STOCK PURCHASE AGREEMENTStock Purchase Agreement • April 30th, 2015 • Incyte Corp • Services-commercial physical & biological research • Delaware
This Stock Purchase Agreement (this “Agreement”) is dated as of January 9, 2015, between Agenus Inc., a Delaware corporation (the “Company”), and Incyte Corporation, a Delaware corporation (the “Purchaser”).
AMENDMENT TO EMPLOYMENT AGREEMENT April 13, 2015Employment Agreement • April 30th, 2015 • Incyte Corp • Services-commercial physical & biological research
THIS AMENDMENT to the Employment Agreement (the “Agreement”) by and between INCYTE CORPORATION, a Delaware corporation (the “Company”) and HERVÉ HOPPENOT (the “Executive”), dated as of January 11, 2014.
LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT BY AND BETWEEN AGENUS INC., 4-ANTIBODY AG, INCYTE EUROPE SARL, AND INCYTE CORPORATION, SOLELY FOR PURPOSES OF SECTION 12.16License, Development and Commercialization Agreement • April 30th, 2015 • Incyte Corp • Services-commercial physical & biological research
THIS LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (the “Agreement”) is entered into as of January 9, 2015 (the “Execution Date”) by and between Agenus Inc., a Delaware corporation having its principal office at 3 Forbes Road, Lexington, Massachusetts 02421, USA (“Agenus US”) and its wholly-owned subsidiary, 4-Antibody AG, a stock corporation organized under the laws of Switzerland with an office at Hochbergerstrasse 60C, CH-4057, Basel, Switzerland (“4-AB” and, together with Agenus US other than with respect to Section 12.17(s), “Agenus”), and Incyte Europe Sarl, a Swiss limited liability company (a société à responsabilité limitée) having its principal office at Cours de Rive 13, 1204, Geneva, Switzerland (“Incyte”) and solely for purposes of Section 12.16, Incyte Corporation, a Delaware corporation having its principal office at 1801 Augustine Cut-off, Wilmington, Delaware 19803 USA (“Parent”). Agenus and Incyte may be referred to in this Agreement individually as a “Party” a
